Who makes Nafarelin acetate, Oestradiol Valerate, Progesterone?

Nafarelin acetate, Oestradiol Valerate, Progesterone is developed by University of Oxford.

What development phase is Nafarelin acetate, Oestradiol Valerate, Progesterone in?

Nafarelin acetate, Oestradiol Valerate, Progesterone is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Nafarelin acetate, Oestradiol Valerate, Progesterone

University of Oxford · FDA-approved active Small molecule Quality 2/100

Nafarelin acetate, Oestradiol Valerate, and Progesterone are marketed drugs developed by the University of Oxford, with a key composition patent expiring in 2028. The combination's primary strength lies in its well-established mechanism and market presence, supported by robust clinical trial results. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	Nafarelin acetate, Oestradiol Valerate, Progesterone
Also known as	Synarel,Progynova,Cyclogest
Sponsor	University of Oxford
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Natural Versus HRT Cycles in Frozen Embryo Replacement Treatment (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nafarelin acetate, Oestradiol Valerate, Progesterone CI brief — competitive landscape report
Nafarelin acetate, Oestradiol Valerate, Progesterone updates RSS · CI watch RSS
University of Oxford portfolio CI